Open access · CC-BY
via OpenAlex
Arterial stiffness, hypertension, and rational use of nebivolol
Vascular Health and Risk Management · 2009 · ▲ 83 citations
Abstract
Arterial stiffness plays a key role in the pathophysiology of the cardiovascular system. Some indices of arterial stiffness (pulse wave velocity, augmentation index, characteristics of central blood pressure waveform) may be presently calculated and evaluated in the clinical setting. Age and blood pressure are the two major clinical determinants of increased arterial stiffness, while molecular determinants of arterial stiffness are related to fibrotic components of the extracellular matrix, mainly elastin, collagen and fibronectin. Increased arterial stiffness has been consistently observed in conditions such as hypertension, dyslipidemia and diabetes. Arterial stiffness evaluated by means of carotid-femoral pulse wave velocity yielded prognostic significance beyond and above traditional risk factors. A more favorable effect of calcium channel blockers, diuretics and ACE inhibitors compared with beta-blockers on indices of arterial stiffness was observed in several studies. It is conceivable that newer beta-blockers with additional vasodilating properties, such as nebivolol, which has favorable effects on carbohydrate and lipid metabolism, as well as on endothelial function and on oxidative stress, may have favorable effects on arterial stiffness, compared with atenolol. In fact, in recent studies, nebivolol was demonstrated to improve artery stiffness to a greater extent than older beta-blockers. Because endothelial dysfunction and increased arterial stiffness play an important role in the early atherosclerotic processes and are associated with poor outcomes and increased mortality, independently of blood pressure, the ability of nebivolol to enhance release of endothelium-derived nitric oxide, and consequently improve endothelial function and arterial stiffness, may have significant clinical implications for the use of this agent in the treatment of hypertension and cardiovascular diseases.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.2147/vhrm.s3056
- Canonical
- link ↗
- Fetched
- 2026-10-19 MST
Cite this
APA
Agabiti‐Rosei, E. (2009). Arterial stiffness, hypertension, and rational use of nebivolol. <em>Vascular Health and Risk Management</em>. https://doi.org/10.2147/vhrm.s3056
Vancouver
Agabiti‐Rosei E. Arterial stiffness, hypertension, and rational use of nebivolol. Vascular Health and Risk Management. 2009. doi:10.2147/vhrm.s3056.
BibTeX
@article{enrico2009Arteri,
title = {Arterial stiffness, hypertension, and rational use of nebivolol},
author = {Enrico Agabiti‐Rosei},
journal = {Vascular Health and Risk Management},
year = {2009},
doi = {10.2147/vhrm.s3056},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Hypertension 2004
Citation only
Arterial Stiffness and Kidney Function
World Journal of Cardiology 2015
Open access · CC-BY
Therapeutic modification of arterial stiffness: An update and comprehensive review
Journal of Family Medicine and Primary Care 2024
Open access · CC-BY
Arterial stiffness as a screening tool for cardiovascular risk in health and disease
Sex- and Gender-Specific Biomedicine 2026
Open access · CC-BY
Sex-Specific Determinants of Arterial Stiffness in Patients with Cardiovascular Risk Factors
Frontiers in Cardiovascular Medicine 2018
Open access · CC-BY
Arterial Stiffness: A Prognostic Marker in Coronary Heart Disease. Available Methods and Clinical Application
Journal of Cardiology 2021
Open access · CC-BY